coMra cases: pancolitis-ulcerative colitis

coMra Case Report: Managing Pancolitis and Ulcerative Colitis

In this case report, Garrett Murrin presents a significant clinical outcome for a patient suffering from pancolitis, a severe form of ulcerative colitis – an inflammatory bowel disease characterized by inflammation and open sores (ulcers) within the colon. This case was submitted by Jana Rudinova, a coMra therapist and nurse representing Radiant Life Technologies in Slovakia.

Patient History and Clinical Presentation

The patient is a 47-year-old male who was first diagnosed with ulcerative colitis in 1990. Initially, his condition was localized to the proctosigmoid region. However, a 2014 colonoscopy confirmed the progression to pancolitis, meaning the inflammation and ulceration had spread throughout the entire colon.

Prior to beginning coMra therapy, the patient experienced severe symptoms, particularly during relapses, which occurred three to four times per year. His symptoms included: * Severe Pain: Abdominal pain and cramping rated at 8 to 10 out of 10 on the pain scale. * Bowel Dysfunction: 12 to 14 stools of diarrhea per day during relapses. * Systemic Symptoms: Presence of blood and mucus in the stool (whenever bowel movements exceeded eight per day), chronic fatigue, and weight loss.

The coMra Treatment Approach

The patient utilized the Delta 980 home-user device. To maximize therapeutic efficacy, the treatment plan involved daily sessions, specifically twice per day for an initial 20-day course. Following the achievement of significant results, the treatment protocol was modified and reduced in consultation with his therapist.

Regarding concurrent pharmacotherapy, the patient had been relying on oral and rectal anti-inflammatories. At the start of his coMra therapy, he was taking five to six pills daily in addition to using suppositories. Since integrating coMra therapy, he has discontinued the use of suppositories entirely and has successfully reduced his oral medication to just two pills per day.

Clinical Results and Quality of Life

The patient’s progress was monitored using fecal calprotectin, a protein found in feces that serves as a non-invasive marker for intestinal inflammation. * September 2013: Marker at 312 (positive indicator for ulcerative colitis). * September 2015: Increased levels noted at the start of care. * February 2016 to Present: Tests indicate no signs of ulcerative colitis.

Beyond the laboratory markers, the patient’s quality of life has improved dramatically: * Bowel Movements: Reduced from an average of five bowel movements per day (mostly diarrhea) to one well-formed stool per day. * Pain Management: The patient has experienced no relapses, pain, or cramps for two years. * Dietary Freedom: He has no current dietary restrictions, with the sole exception of avoiding milk.

Garrett Murrin highlights that the transition from frequent, debilitating relapses to two years of stability represents a profound success. This case underscores the potential of coMra therapy to support the body’s healing capacity and reduce the burden of long-term pharmaceutical reliance.

Radiant Life Technologies extends its gratitude to Jana Rudinova for her dedicated work in this case. As Théun Mares, founder of Radiant Life Technologies, once stated: "The state of well-being is something that has to be experienced before one even knows that it exists. Once it has been discovered, it needs to be nurtured and tended with care." coMra therapy remains a powerful tool for nurturing that sense of well-being.